Cernilton A® approved by KFDA in South Korea

Press release February 27, 2024.

Cernilton A® approved by KFDA in South Korea

AB Cernelle, in close and trusted partnership with DongKoo Bio&Pharma Co, Ltd, a leading Korean pharmaceutical company with focus in urology, allergy and dermatology, has been granted approval of Cernilton A® by the medical product agency KFDA in South Korea.
Cernilton A®, is a herbal medicinal product for treatment of benign prostate diseases; Chronic Prostatitis and Benign Prostate Enlargement.
Preparation for the market launch of Cernilton A®, has been initiated and the product is expected to be available for sale in May/June 2024.
There is an unmet medical need in Korea to treat especially Chronic Prostatitis. Cernilton A® is the only medicinal product that has been approved for treatment of this indication.
Continued close cooperation between Cernelle and DongKoo will now focus on the market launch and introduction of Cernilton A®.

• “Cernilton A® with effectiveness and safety will advance the standard of care for the benefit of people with benign prostate diseases. Also, it will secure DongKoo’s position as one of the leading companies within medical urology.” says DongKoo CEO, Yongjoon Cho.
• “This provides Cernelle with a fantastic opportunity in Korea, and in the near future we expect approval of Cernilton A® in several ASEAN markets” says Cernelle CEO, Ken Tinebo.

Intensive work on several projects is ongoing at the facility outside of Ängelholm to increase production capacity and boost Cernelle into a world leading position in pollen extraction and products for medicinal use, focusing on benign prostate disorders.

• “To achieve this, we need more qualified, dedicated co-workers with the energy and drive to help us in our meaningful work at Cernelle. Recruiting the right people is the key to continued success for the company,” says Ken Tinebo.

Further information: Ken Tinebo, CEO Cernelle, +46 (0)730-877 637, ken.tinebo@cernelle.se

About AB Cernelle
Cernelle is a Swedish pharmaceutical company with research, development, production, and distribution of medicinal products in the urology segment; chronic prostatitis (CP), pelvic pain (CPP) and benign prostatic enlargement (BPE). Cernelle has been developing herbal pharmaceutical products from high-quality pollen extract since 1953. With more than 2,3 billion daily doses distributed, Cernilton®/Cernitol® is one of the world’s most widely used medicine to treat benign prostate diseases. The company has 40 employees, located at the facilities outside Ängelholm in Southern Sweden. Since 2021 Cernelle is owned by the German pharmaceutical company Dermapharm AG. www.cernelle.com